RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.61%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$870M
AUM Growth
+$870M
(-11%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-12.27%
Top 10 Holdings %
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10
Top Buys
| 1 |
Glaukos
GKOS
|
$23M |
| 2 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 3 |
Elevance Health
ELV
|
$11.2M |
| 4 |
Molina Healthcare
MOH
|
$11.2M |
| 5 |
DexCom
DXCM
|
$10.6M |
Top Sells
| 1 |
Merck
MRK
|
$21.9M |
| 2 |
Inspire Medical Systems
INSP
|
$21.4M |
| 3 |
Cigna
CI
|
$16.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$14.7M |
| 5 |
Boston Scientific
BSX
|
$14.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
IQVIA
IQV
$31.4B
| $3.88M | 0.45% |
22,000
-7,000
| -24% | -$1.23M |
|
52
Janux Therapeutics
JANX
$1.38B
| $3.82M | 0.44% |
141,627
-28,373
| -17% | -$766K |
|
53
Encompass Health
EHC
$12.5B
| $3.79M | 0.44% |
37,400
-18,600
| -33% | -$1.88M |
|
54
Akero Therapeutics
AKRO
$3.65B
| $3.74M | 0.43% |
+92,500
| New | +$3.74M |
|
55
Nuvalent
NUVL
$5.74B
| $3.72M | 0.43% |
52,500
-20,000
| -28% | -$1.42M |
|
56
Mirum Pharmaceuticals
MIRM
$3.75B
| $3.32M | 0.38% |
73,755
| – | – |
|
57
BioNTech
BNTX
$24.1B
| $3.26M | 0.37% |
35,750
-17,000
| -32% | -$1.55M |
|
58
Krystal Biotech
KRYS
$4.35B
| $3.2M | 0.37% |
17,750
-6,000
| -25% | -$1.08M |
|
59
Merus
MRUS
$5.04B
| $3.14M | 0.36% |
74,500
| – | – |
|
60
Ultragenyx Pharmaceutical
RARE
$3.04B
| $2.97M | 0.34% |
+82,000
| New | +$2.97M |
|
61
Nurix Therapeutics
NRIX
$723M
| $2.96M | 0.34% |
249,336
-40,664
| -14% | -$483K |
|
|
62
Merck
MRK
$210B
| $2.96M | 0.34% |
33,000
-244,500
| -88% | -$21.9M |
|
63
Arcellx
ACLX
$3.95B
| $2.85M | 0.33% |
43,500
| – | – |
|
|
64
Inspire Medical Systems
INSP
$2.53B
| $2.55M | 0.29% |
16,000
-134,041
| -89% | -$21.4M |
|
65
Ionis Pharmaceuticals
IONS
$9.64B
| $2.44M | 0.28% |
81,000
-131,500
| -62% | -$3.97M |
|
66
Viking Therapeutics
VKTX
$3.02B
| $2.42M | 0.28% |
100,000
+10,000
| +11% | +$242K |
|
67
Dianthus Therapeutics
DNTH
$781M
| $2.3M | 0.26% |
126,627
+12,627
| +11% | +$229K |
|
68
Privia Health
PRVA
$2.85B
| $2.2M | 0.25% |
98,189
-23,000
| -19% | -$516K |
|
69
Iovance Biotherapeutics
IOVA
$800M
| $2.16M | 0.25% |
647,827
-587,621
| -48% | -$1.96M |
|
70
Xencor
XNCR
$594M
| $2.08M | 0.24% |
195,750
| – | – |
|
71
Bruker
BRKR
$4.45B
| $1.77M | 0.2% |
42,315
+6,000
| +17% | +$250K |
|
72
MoonLake Immunotherapeutics
MLTX
$3.78B
| $1.76M | 0.2% |
+45,000
| New | +$1.76M |
|
73
Esperion Therapeutics
ESPR
$490M
| $1.54M | 0.18% |
1,066,495
-848,505
| -44% | -$1.22M |
|
74
INmune Bio
INMB
$52.4M
| $1.39M | 0.16% |
178,284
| – | – |
|
75
Denali Therapeutics
DNLI
$2.24B
| $1.36M | 0.16% |
+100,000
| New | +$1.36M |
|